Related by context. All words. (Click for frequent words.) 68 pancreatic lung 68 ovarian lung 67 ovarian breast 67 prostate lung 66 breast colon 66 colorectal lung 65 breast ovary 65 colorectal prostate 65 ovarian colon 65 lung colorectal 65 bladder cancers 65 prostate colon 65 lung colon 65 breast colorectal 64 lung prostate 64 cervical breast 64 pancreatic prostate 64 Squamous cell 64 breast ovarian 63 prostate pancreatic 63 ovarian pancreatic 63 lung pancreatic 63 colon prostate 63 pancreatic colon 63 hormone refractory prostate 63 ovarian prostate 62 colorectal breast 62 colon breast 62 pancreatic cancers 62 breast prostate 62 cancers 62 bladder ovarian 62 colon pancreatic 62 prostate colorectal 62 skeletal metastases 61 metastatic colorectal 61 precursor lesions 61 epithelial tumors 61 breast uterine 61 breast pancreatic 61 gastrointestinal cancers 61 breast endometrial 61 testicular cancers 61 gastric cancers 61 colon pancreas 61 adenocarcinomas 61 endometrial cancers 60 malignancies 60 uterine ovarian 60 Colon polyps 60 basal cell carcinoma squamous 60 colon lung 60 carcinomas 60 colorectal cancers 60 endometrial ovarian 60 neuroendocrine cancers 60 epithelial cancers 60 Basal cell 60 osteosarcomas 60 distant metastasis 60 gastric pancreatic 59 pancreatic bladder 59 pancreatic ovarian 59 pancreatic colorectal 59 neuroendocrine tumors 59 hematological disorders 59 kidney urologic 59 pancreatic gastric 59 colorectal ovarian 59 prostate ovarian 59 metastases 59 tumor metastasis 59 esophagus colon 59 nonmelanoma skin cancers 58 multiple sclerosis psoriasis 58 CYT# potent vascular disrupting 58 pulmonary metastases 58 lobular carcinoma 58 colorectal pancreatic 58 metastatic cancers 58 metastasis 58 colon esophageal 58 colorectal bladder 58 rectal cancers 57 adrenocortical cancer 57 cirrhosis liver failure 57 unresectable tumors 57 colorectal gastric 57 lymphomas leukemias 57 Papillary 57 carcinoid 57 adenomatous polyps 57 JNK pathway 57 uterine cancers 57 renal cell carcinomas 57 breast cervical 57 bladder prostate 57 BRCA deficient 57 delay bone metastases 57 hormone receptor negative 57 Acute myeloid leukemia AML 57 bone metastasis 57 colorectal cancer CRC 57 hormonally sensitive 57 sarcomatoid 57 Alessandro Riva 57 carcinoma HCC 57 endometrial kidney 57 HER signaling pathway 57 prostate cancers 57 lung carcinomas 57 LHRH receptor positive 57 solid tumors 56 hematological diseases 56 hormone gastrin 56 ductal carcinomas 56 colon cancers 56 oncogenesis 56 Basal Cell 56 myeloproliferative neoplasms 56 leukaemias 56 papillary renal cell carcinoma 56 myelofibrosis polycythemia vera 56 ovarian colorectal 56 ovarian endometrial 56 esophageal cancers 56 liver metastasis 56 SPINK1 56 colorectal carcinoma 56 K ras mutations 56 metastatic pancreatic 56 Medullary thyroid cancer 56 nonmetastatic 56 breast carcinomas 56 epithelial tissues 56 sarcoma melanoma 56 pancreas esophagus 56 serous ovarian cancer 56 ovarian cervical 56 Carcinoid tumors 56 metachronous 56 tumor metastases 56 metastatic lesions 56 c MET 56 nodal metastasis 56 ovarian uterine 56 endometrial hyperplasia 56 lobular carcinomas 56 cardiovascular disease hypertension 56 essential thrombocythemia ET 56 prostate bladder 55 lobular cancer 55 psoriasis rheumatoid arthritis 55 pediatric acute lymphoblastic 55 squamous cell carcinomas 55 bone marrow lymph nodes 55 fallopian tube cancers 55 hematologic malignancies 55 lobular breast cancer 55 prostate carcinomas 55 squamous cell cancers 55 IGF IR 55 uterine cervix 55 gynecologic malignancy 55 molecular abnormalities 55 pancreatic adenocarcinoma 55 liver cancers hypercholesterolemia 55 MCSP respectively 55 deCODE BreastCancer 55 neoplasms 55 lymphoma subtypes 55 metastatic HER2 positive 55 dysplastic lesions caused 55 leukemia myeloma 55 immunodeficiency disorders 55 advanced adenomas 55 Menopausal hormone therapy 55 leiomyomas 55 seminoma 55 adhesion molecule EpCAM expressing 55 squamous cell carcinoma SCC 55 Inflammatory bowel diseases 55 HER2 ErbB2 55 Cholangiocarcinoma 55 lymphoid malignancies 55 myeloproliferative diseases 55 breast carcinoma 55 tumor xenograft models 55 oesophageal adenocarcinoma 55 colorectum 55 chemo resistant 55 castrate resistant 55 benign neoplasms 55 nonmelanoma 55 ATC ovarian cancer 55 antiangiogenesis therapies 55 inflammatory autoimmune diseases 55 Thyroid nodules 55 epithelioid 54 TTR amyloidosis 54 androgen dependent 54 hematologic disorders 54 Metastatic 54 Acute lymphoblastic leukemia 54 TNF blocker therapy 54 medullary thyroid cancer 54 lymphoid tumors 54 intestinal polyps 54 KRAS oncogene 54 gastric carcinoma 54 Gliomas 54 urothelial carcinoma 54 Epidermal Growth Factor Receptor 54 cardio metabolic diseases 54 atypical hyperplasia 54 Evoltra ® 54 ovarian carcinoma 54 HBeAg negative 54 penile cancers 54 essential thrombocythemia 54 endocrine therapies 54 premalignant 54 neoplastic 54 Basal cell carcinomas 54 ovarian cancers 54 mutated KRAS gene 54 colorectal 54 oligodendrogliomas 54 detect precancerous lesions 54 nonsmall cell lung cancer 54 hamartomas 54 Endometrial cancer 54 gastro intestinal inflammation 54 prostate cancer CaP 54 testicular tumors 54 factor receptor EGFR 54 tumor vascularization 54 squamous cell skin 54 systemic autoimmune 54 HER2 overexpression 54 neoplastic lesions 54 Renal cell carcinoma 54 oncological indications 54 colorectal tumors 54 HER2 positive breast 54 histologies 54 ductal breast cancer 54 neoplasias 54 HNSCC 54 promoter hypermethylation 54 breast cancer metastasis 54 ribonucleotide reductase clinically validated 54 Metastases 54 squamous cell 54 LHRH analogues 54 CD# CEA 54 autoimmune disorders 54 multiple sclerosis rheumatoid arthritis 54 ductal cancer 54 prostate carcinoma 54 SETDB1 54 leukemias lymphomas 54 pancreatic endocrine 54 Squamous cell carcinomas 54 chemotherapy induced neutropenia 54 adenomatous 54 IgG1 monoclonal antibody 54 HIV AIDS neuropathic pain 53 cutaneous melanoma 53 sorafenib tablets 53 rheumatoid arthritis juvenile idiopathic 53 EGFR mutant 53 mesenchymal cell 53 sickle cell cystic fibrosis 53 commercialize deforolimus 53 Glioblastoma multiforme GBM 53 basal cell cancer 53 inhibiting tumor 53 hepatocellular 53 preclinical xenograft models 53 invasive ductal 53 candidates Azedra TM 53 seminomas 53 squamous cell lung cancer 53 lymph node metastases 53 rheumatoid arthritis multiple sclerosis 53 lung cancers 53 lymph node enlargement 53 hepatocellular carcinoma 53 Squamous 53 lung cancer NSCLC 53 melanoma basal cell 53 chronically immunosuppressed solid 53 lupus multiple sclerosis 53 antisense inhibitors 53 node metastases 53 invasive lobular 53 rheumatoid arthritis gout 53 immunological diseases 53 proliferative disorders 53 thromboembolic disease 53 faulty BRCA genes 53 esophageal tumors 53 epithelial ovarian 53 immunotherapeutic approaches 53 abnormal p# 53 prostate TURP 53 endometriosis ovarian cysts 53 imatinib Gleevec 53 malignant growths 53 HER2 neu 53 gynecological cancers 53 lymph node metastasis 53 gastric adenocarcinoma 53 pheochromocytoma 53 Vidaza ® 53 androgen independent 53 resistant hormone refractory 53 myelomas 53 mediated autoimmune diseases 53 noncancerous tumors 53 lymphoid tissue 53 progesterone receptor negative 53 tissue fibrosis 53 liver cancers TTR 53 histological subtype 53 metastatic lymph nodes 53 myeloproliferative disorders 53 proliferative diseases 53 Chronic myeloid leukemia CML 53 lymphomas 53 cell lymphomas 53 bevacizumab Avastin ® 53 pituitary adenomas 53 Zemiva TM 53 sirtuin inhibitor program 53 rheumatoid arthritis psoriasis 53 malignant tumors 53 Solazed TM 53 cMET 53 adjuvant therapies 53 lymphangiogenesis 53 prostate adenocarcinoma 53 gastrointestinal mucositis 53 HER2 positive cancers 53 Acute myeloid leukemia 53 beta1 integrin 53 anal cancers 53 basal cell carcinoma BCC 53 uPA 53 penile anal 53 HER1 53 metastatic prostate 53 ocular disorders 53 Leukemias 53 recurrent metastatic 53 vascular disorders 53 ovary uterus 53 pulmonary metastasis 53 distant metastases 53 nasopharyngeal carcinoma 53 prokinetic agent 53 inflammatory disorders 53 cisplatin resistant 53 basal cell carcinomas 53 cervical carcinoma 53 multiple sclerosis Crohn disease 53 gastric cardia 53 TTR gene 52 unknown etiology 52 Uterine fibroids 52 situ CIS 52 squamous 52 metastatic bladder 52 Raf MEK ERK 52 matrix metalloproteinases 52 pathological hallmark 52 M2 subunit 52 NF kB pathway 52 hereditary predisposition 52 renal carcinoma 52 rheumatoid arthritis thrombocytopenia 52 novel VDA molecule 52 vinca alkaloids 52 carcinoma 52 immunological disorders 52 prostaglandin D2 52 TRAIL receptor antibodies 52 cardiometabolic disorders 52 malignant neoplasm 52 trans retinoic acid 52 glioma rarer 52 RANK ligand 52 metastatic GIST 52 dasatinib Sprycel 52 Colorectal cancer CRC 52 PGDH 52 Pancreatic neuroendocrine tumors 52 rheumatoid arthritis lupus 52 IMC #B 52 tumor subtypes 52 R Saizen R 52 signal transduction inhibitors 52 metastatic tumors 52 castration resistant 52 orally administered inhibitor 52 EGFR mutation 52 ipsilateral breast 52 gastrin 52 cancer mCRC 52 Radical prostatectomy 52 colorectal adenoma 52 malignant neoplasms 52 proximal colon 52 CEA CD# Her2 52 c MYC 52 PKCi 52 nonproliferative 52 inducible nitric oxide synthase 52 epithelial origin 52 GATA3 52 anti angiogenic therapies 52 transplantation HCT 52 atypical ductal hyperplasia 52 HER2 receptors 52 systemic fungal infections 52 Factor Receptor 52 products MKC# PP 52 HER2 positive 52 bowel cancers 52 sodium thiosulfate STS 52 hepatocellular carcinomas 52 gastroenterology neurology 52 testicular germ cell 52 commonly mutated genes 52 non alcoholic steatohepatitis 52 BRCA2 carriers 52 secondary hyperparathyroidism 52 medically inoperable 52 QUADRAMET R 52 cetuximab Erbitux 52 Sezary syndrome 52 precancers 52 uterine tumors 52 metastatic liver 52 histologic subtype 52 excess TNF alpha 52 neoplastic diseases 52 pancreatic islet cell 52 immunodeficiencies 52 antiproliferative effects 52 papillary 52 HER2 amplified 52 EGFR pathway 52 poly ADP ribose polymerase 52 Basal cell carcinoma 52 sPLA2 52 metastatic disease 52 fusion enhancers 52 VEGF expression 52 basal cell nevus syndrome 52 epilepsy Parkinson disease 52 prostate carcinogenesis 52 epigenetic therapies 52 FLT3 52 gynecologic cancers 52 axillary lymph nodes 52 chemoattractant receptors 52 peritoneal carcinomatosis 52 pre cancerous growths 52 basal cell skin 52 FGFR2 52 PIK3CA 52 breast cancers 52 mTOR inhibitors 52 carcinoid tumors 52 gastroesophageal junction 52 thyroid carcinomas 52 serine proteases 52 hematologic cancers 52 prognostic markers 52 hematological malignancies 52 Malignant tumors 52 basal cell 52 protein tyrosine phosphatase 1B 52 metastatic 52 cyclin E 52 factor PlGF 52 hCG beta 52 GISTs 52 glioblastoma tumor 52 trastuzumab resistant 52 LRP5 52 xenograft models 52 nonalcoholic steatohepatitis 52 erlotinib Tarceva ® 52 neuropathic pain nerve 52 extrahepatic 52 chronic eosinophilic leukemia 52 oncogenes 52 Helicobacter pylori infection 52 anthracycline taxane 52 Tay Sachs thalassemia 52 CTAP# Capsules 52 advanced hepatocellular carcinoma 52 Exherin TM 52 hepatocellular cancer 52 GSTP1 52 lipid abnormalities 52 tumors GIST 51 RNAi therapeutic targeting 51 anti angiogenic agents 51 TRIOLEX HE# APOPTONE HE# 51 androgen receptor AR 51 bacterial biothreat agents 51 EGFR inhibitors 51 HER2 receptor 51 oncogenic pathways 51 Li Fraumeni 51 oesophageal cancers 51 neuropsychiatric diseases 51 orally bioavailable mimics 51 pathophysiological effects 51 investigational therapies 51 ErbB2 positive 51 gastrointestinal stromal tumors GISTs 51 intimal hyperplasia 51 activated lymphocytes 51 Glioblastomas 51 cyclooxygenase 2 51 HbF 51 colorectal cancer 51 hematologic diseases 51 premalignant lesions 51 TLR9 agonists 51 including eniluracil ADH 51 histone deacetylase HDAC 51 prophylactic vaccines 51 FGFR 51 Clusterin 51 receptor tyrosine kinase inhibitor 51 BRCA1 mutation carriers 51 situ LCIS 51 leiomyoma 51 LHRH antagonists 51 gastrointestinal disorders ATI 51 hormonal therapies 51 Human papilloma virus 51 degenerative disorders 51 PI3K AKT 51 cancerdefine 51 cyclin dependent kinases CDKs 51 ThermoDox R 51 malignant prostate 51 Ribavirin causes 51 Genetic variations 51 pelvic malignancies 51 EGFR HER2 51 stem cells CSCs 51 BRCA2 mutations 51 PCA3 gene 51 autoimmune diseases inflammation 51 diabetes cardiovascular disease 51 neuroblastomas 51 COX2 51 precancerous tumors 51 gastrointestinal malignancies 51 EGFR mutations 51 HER2 positive tumors 51 intracellular pathways 51 frequently benign tumor 51 neurovascular diseases 51 systemic lupus erythematosus lupus 51 FGFs 51 spongiform encephalopathies 51 chemopreventive agent 51 germline mutations 51 malignant pheochromocytoma 51 malignant lymphomas 51 tauopathies 51 refractory metastatic 51 Sarcomas 51 neoplasia 51 extranodal 51 contralateral breast 51 TNFalpha 51 factor HGF 51 tumors 51 Surgical resection 51 biologic pathway 51 estrogen receptors 51 kinase PI3K pathway 51 cell motility 51 colon polyps 51 mucinous 51 chemopreventive agents 51 MEK inhibitors 51 TGF alpha 51 V#F mutation 51 vaccine GRNVAC1 51 lymphoid 51 HER2 expression 51 A3 adenosine receptor 51 recurrent ovarian 51 diseases fat malabsorption 51 neovascular diseases 51 gefitinib Iressa 51 immune dysregulation 51 C1 INH deficiency 51 Adjuvant chemotherapy 51 postmenopausal hormone 51 metastatic renal 51 prognostic indicator 51 FGFR3 51 MUC1 51 delta isoform 51 inflammation thrombosis oncology 51 cachexia anti infectives 51 sunitinib Sutent 51 genitourinary tract 51 solar keratosis 51 sarcomas 51 biliary cancer 51 hypertension hypercholesterolemia 51 MEK ERK 51 carcinogenesis 51 haematological malignancies 51 advanced carcinoid 51 Kit CD# positive 51 endometrial carcinoma 51 Vandetanib 51 Systemic lupus erythematosus 51 carcinoembryonic antigen 51 oncologic diseases 51 malignant lesions 51 investigational monoclonal antibody 51 MAPK pathway 51 luteinizing hormone releasing 51 gastrointestinal stromal tumor 51 nonalcoholic steatohepatitis NASH 51 CD# expressing 51 intracellular signaling pathways 51 fungal infections malaria tuberculosis 51 molecular biomarkers 51 superficial basal cell carcinoma 51 chemokine receptors 51 Systemic lupus erythematosus SLE 51 AAG geldanamycin analog 51 hypermethylated 51 mutated K ras 51 Epstein Barr Virus EBV 51 Androgen deprivation therapy 51 salpingo oophorectomy 51 desmoplastic 51 tumoral 51 JAK inhibitors 51 hypoxia inducible factor 51 EGFR tyrosine kinase inhibitors 51 hypopharynx 51 hypereosinophilic syndrome 51 situ DCIS 51 adenomatous polyp 51 hematological indications 51 pre malignant lesions 51 tubulin inhibitor 51 lymph node removal 51 liver scarring 51 apoptotic pathway 51 diagnostic biomarkers 51 nonmelanoma skin cancer 51 inhibit EGFR 51 hyperparathyroidism 51 anemias 51 Peritoneal mesothelioma 51 severe degenerative ischemic 51 H. pylori eradication 51 ALN TTR 51 histone deacetylase inhibitor 51 RAS RAF MEK 51 endosomal release 51 gastrointestinal stromal tumors 51 MGd 51 intra abdominal abscess 51 inhibit metastasis 51 pan HDAC inhibitor 51 squamous cell cancer 51 papillomas 51 tumor stroma 51 colorectal polyps 50 lymphatic tissue 50 mapatumumab 50 antimitotic 50 male hormones androgens 50 suppresses tumor 50 abnormal pap smears 50 proliferation apoptosis 50 liver metastases 50 PDGFR 50 thalidomide Thalomid 50 Uterine cancer 50 ALN PCS 50 protein tyrosine phosphatases 50 VIPR2 50 astrocytomas 50 synovial cells 50 mesotheliomas 50 cervical uterine 50 MKC# MT 50 hyperplasia 50 Proxinium TM 50 signal transduction pathways 50 Ischemic strokes 50 anaplastic 50 RAF kinase VEGFR 50 Systemic lupus 50 retinoic acid receptor 50 glial tumors 50 intrahepatic 50 aromatase inhibitors AIs 50 demonstrated antitumor activity 50 blood coagulation disorders 50 Hypoxia Inducible Factor 50 arterial calcification 50 Everolimus 50 myopathies 50 humanized monoclonal antibodies 50 c myc gene 50 Synovial sarcoma 50 invasive carcinoma 50 standard chemotherapy regimens 50 Candida infection 50 oncogenic transformation 50 biliary tract cancer 50 advanced adenoma 50 metastatic neuroendocrine tumors 50 rheumatoid arthritis psoriatic arthritis 50 colorectal polyp 50 IMC A# 50 BRCA1 BRCA2 50 GVAX ® 50 dysplastic nevi 50 bone metastases 50 Chronic Lymphocytic Leukemia CLL 50 specific lectin receptors 50 receptor gamma 50 R sorafenib tablets 50 SUVmax 50 novel immunotherapies 50 allogeneic HSCT 50 endometrial 50 carcinoids 50 oncology indications 50 macrovascular events 50 carcinoid tumor 50 non Hodgkin lymphomas 50 RANKL 50 Myelodysplastic syndromes MDS 50 hyperplastic 50 aberrant activation 50 Endometrial 50 neoplastic cells 50 anti apoptotic proteins 50 leukemias 50 Acoustic neuromas 50 MALT lymphoma 50 androgen deprivation 50 locoregional recurrence 50 gemcitabine Gemzar 50 Pleural mesothelioma 50 cervical dysplasia 50 neuro degenerative diseases 50 oncoproteins 50 cervical intraepithelial neoplasia 50 Metastatic breast cancer 50 KRAS mutations 50 BRCA mutations 50 histone deacetylation 50 caveolin 1 50 epigenomics 50 differentiated thyroid 50 lung cancer asbestosis 50 pertuzumab 50 angiogenesis inhibitors 50 Bone metastases 50 Cutaneous T 50 colon rectal 50 infectious diseases autoimmune diseases 50 Apaziquone 50 specific antigen PSA 50 malignant ovarian 50 biologic pathways 50 targeted radiotherapeutic 50 Wnt signaling pathway 50 alpha#beta# 50 thromboxane A2 50 glioblastoma multiforme GBM 50 Hepatocellular carcinoma 50 basal cell cancers 50 CMV disease 50 mutated BRAF gene 50 cancerous enlargement 50 endometrial tumors 50 Parkinson disease Alzheimer disease 50 recurrent NSCLC 50 alvespimycin 50 cathepsins 50 molecular subtypes 50 including thyroiditis RA 50 GBM tumors 50 Src kinase 50 Tavocept 50 ThermoDox ® clinical 50 ductal adenocarcinoma 50 tumor histology 50 malignant fibrous histiocytoma 50 selective angiogenic kinase inhibitor 50 genes BRCA1 50 ERBB2 50 ductal 50 Fibroid tumors 50 YONDELIS 50 Leydig cell 50 samarium Sm 50 intestinal metaplasia 50 cervical lymph nodes 50 PI3K Akt 50 hepatocellular carcinoma HCC 50 granulosa cell 50 endogenous estrogen 50 Panzem R 50 Irinotecan 50 thyroid carcinoma 50 Androgen 50 lymphoid organs 50 histologic subtypes 50 pancreatic carcinoma 50 candida infections 50 vascular constriction 50 recurrent glioblastoma multiforme GBM 50 adrenal hormone 50 myeloperoxidase 50 metaglidasen 50 immunology oncology 50 hypercholesterolemia liver 50 organ transplant rejection 50 NMIBC 50 AEG# 50 rheumatoid arthritis systemic lupus 50 Li Fraumeni Syndrome 50 hormone refractory 50 castrate resistant prostate cancer 50 precancerous cervical 50 GSTT1 50 HDAC inhibition 50 malignant brain 50 GnRH agonists 50 IL #p# 50 liver fibrosis 50 aerodigestive tract 50 grade serous ovarian 50 autoimmune diseases 50 Elotuzumab 50 Aurora kinase 50 fallopian tube carcinoma 50 lymphoid tissues 50 underarm lymph nodes 50 colorectal adenocarcinoma 50 engineered RAP peptides 50 proinflammatory cytokines 50 mediated amyloidosis ATTR hypercholesterolemia 50 benign growths 50 endometrial cancer 50 cholangiocarcinoma 50 eIF 4E 50 lung adenocarcinomas 50 acute leukemias 50 activated microglia 50 inhibits tumor 50 gastric cancer 50 radiosensitive 50 metastatic HER2 negative 50 de ath 50 hormone receptor positive 50 GRNOPC1 contains 50 pAkt 50 certain protein tyrosine 50 lupus scleroderma 50 telomerase inhibition 50 AGTR1 50 lung adenocarcinoma 50 lymph node involvement 49 pain syndromes 49 clinically validated targets 49 benign noncancerous 49 gemcitabine chemotherapy 49 activating mutations 49 Oxidative damage 49 Interferon beta 49 precancerous condition 49 aromatase enzyme 49 mutant p# 49 BRAF mutations 49 TNFa 49 metastatic androgen independent 49 fibrogenesis 49 schwannomas 49 Oncogenes 49 non resectable 49 primary hyperparathyroidism 49 IRX 2 49 grade gliomas 49 breast tumors 49 related apoptosis inducing 49 docetaxel Taxotere ® 49 oral squamous cell 49 p# biomarker 49 adenocarcinoma 49 HER2 positive metastatic breast 49 myeloid cells 49 microvascular complications 49 lintuzumab SGN 49 Medulloblastoma 49 follicular lymphoma FL 49 familial pancreatic cancer 49 BRAF inhibitor 49 lymphoproliferative disorders 49 anti amnesic 49 CLL SLL 49 neoadjuvant therapy 49 miR #a [002] 49 Provectus Pharmaceuticals specializes 49 atherosclerotic disease 49 urothelial cancer 49 radiosensitivity 49 chronic periodontitis 49 familial amyloidotic polyneuropathy FAP 49 MPS IVA 49 macrovascular complications 49 immuno modulatory 49 angiogenic responses 49 heavily pretreated 49 progesterone receptor PR 49 epithelial cell 49 hyperphosphorylation 49 squamous histology 49 metaplasia 49 NSCLC tumors 49 cell adhesion molecule 49 Upregulation 49 MYCN amplification 49 cell acute lymphoblastic 49 cervical lesions 49 unresectable liver cancer 49 nasopharyngeal cancer 49 invasive carcinomas 49 monogenic diseases 49 oral prodrug 49 ophthalmology oncology 49 Sudhir Agrawal D.Phil 49 colon tumors 49 papillomaviruses 49 lactate dehydrogenase 49 metabolism viral replication 49 kinase PI3K Akt pathway 49 Glioblastoma Multiforme 49 pro inflammatory cytokines 49 APOPTONE 49 malignant cancerous 49 novel therapeutic antibodies 49 colorectal carcinomas 49 precancer 49 NFκB 49 motor neuron degeneration 49 Combivir Kivexa 49 beta catenin protein 49 leukemia AML 49 skeletal muscle weakness 49 somatic mutations 49 leukotriene pathway 49 cervix uteri 49 neointimal 49 ovarian 49 KRAS mutant 49 benign polyps 49 mycosis fungoides 49 precancerous colon polyps 49 VEGF inhibitors 49 B Cell Lymphoma 49 Sentinel node biopsy 49 osteoclast activity 49 lipomas 49 TMEM#B 49 metastatic breast 49 autoreactive T cells 49 cystic fibrosis muscular dystrophy 49 cell malignancies 49 EZH2 49 receptors EGFR 49 phosphate S1P